Preclinical and clinical results with an ultrasonic contrast agent

Effect of microbubble contrast on intracranial blood flow velocity assessed by transcranial Doppler

PURPOSE

Ultrasound contrast agents (UCA) salvage a considerable number of transcranial Doppler (TCD) exams which would have failed because of poor bone window. UCA bolus injection causes an undesirable increase in measured blood flow velocity (BFV). The effect of UCA continuous infusion on measured BFV has not been investigated, and some in vitro experiments suggest that gain reduction during UCA administration may also influence measured BFV. This study aimed to investigate the effect of UCA continuous infusion on BFV measured by TCD and the influence of gain reduction on these measurements in a clinical setting.

METHODS

The right middle cerebral artery of ten patients with optimal bone window was insonated using a 2 MHz probe. UCA were administered using an infusion pump. BFV was measured (1) at baseline, (2) during UCA infusion, (3) during UCA infusion with gain reduction, and (4) after UCA wash-out phase. Gain reduction was based on the agreement between two neurosonographers on the degree of gain reduction necessary to restore baseline Doppler signal intensity (DSI). Actual DSI was estimated offline by analysis of raw data.

RESULTS

BFV measured during UCA infusion with no gain adjustment was significantly higher than baseline BFV [peak systolic velocity (PSV): 85.1 ± 19.7 vs. 74.4 ± 19.7 cm/s, p < 0.0001; Mean velocity (MV): 56.5 ± 11.8 vs. 50.2 ± 12.3 cm/s, p < 0.0001]. BFV measured during UCA infusion with gain reduction was not significantly higher than baseline BFV (PSV: 74.3 ± 18.9 vs. 74.4 ± 19.4 cm/s, p = 0.8; MV: 49.4 ± 11.0 vs. 50.2 ± 12.3 cm/s, p = 0.8). Actual DSI during UCA infusion with gain reduction was not significantly higher than baseline DSI (13 ± 1 vs. 13 ± 1 dB).

CONCLUSION

This study shows that UCA continuous infusion leads to an increase in measured BFV which may be counteracted by reducing Doppler gain thus restoring pre-contrast DSI.

Stabilization of Gas Bubbles Released from Water-Soluble Carbohydrates Using Amphiphilic Compounds: Preparation of Formulations and Acoustic Monitoring of Bubble Lifetime

The ultrasound contrast agents Echovist^® and Levovist^® (Bayer AG, Schering AG, Germany) are based on the release of gas bubbles from milled α-d-galactose. In diagnostic ultrasound, for this class of contrast agents, there is a need for prolonged contrast duration. To investigate if new carbohydrate compositions could prolong the lifetime of the gas bubbles, α-d-galactose was mixed with other carbohydrates or amphiphiles with varying log P. Acoustic attenuation vs. time (390 s) area under the curve (A₃₉₀) and bubble half-time (t½) were used as measures of prolonged lifetime of gas bubbles. The products, to which 0.1% of a lipophilic carboxylic acid (5β-cholanic acid, behenic acid, and melissic acid) has been added, showed more than 5, 7 and 11 times enhancement of A₃₉₀, respectively, compared with the reference compound 2 (RC2) corresponding to the commercial product Levovist®. The half-time t ½ of the same compounds was prolonged more than 6 times compared with RC2. A partial least square (PLS) statistical analysis confirmed that, for additives, high log P carboxylic acids lead to the highest A₃₉₀. The present results bear a promise of products with a more persistent in vivo ultrasound contrast effect than the commercially available agents.

Ultraschallkontrastmittel: Substanzklassen, Pharmakokinetik, klinische Anwendungen, Sicherheitsaspekte

Ultrasound contrast agents (UCA) have undergone constant development and improvement in recent years. Greater mechanical stability and improved acoustic properties, combined with new contrast-specific ultrasound sequences, have broadened the potential fields for investigation considerably. Contrast-enhanced ultrasound studies will no longer be complementary investigations, but will be considered as primary techniques. This review article provides a survey of the different drugs used, their chemical properties, and their pharmacokinetic aspects. Summarized are the most important established and published indications for the use of UCA together with an outlook for future applications. Finally this paper discusses the safety profile of these agents, which has become important due to the increasing use of these agents.

Obstetric ultrasonography: a biophysical consideration of patient safety--the "rules" have changed

We address the issue of health and safety in relation to exposure to diagnostic ultrasound, with particular emphasis given to obstetrics. In terms of fetal and maternal outcomes, the epidemiologic record of diagnostic ultrasound is exemplary but is primarily made on the basis of data derived from clinical devices whose outputs were relatively low compared with what is now allowable and available. The power outputs of clinical devices have been increasing over the past decade such that the potential for thermal and nonthermal insults is increased. For obstetric devices that use these higher outputs, the Food and Drug Administration now requires the presentation of 2 on-screen indexes, the thermal index and the mechanical index, in recognition of the 2 major mechanisms by which ultrasonography is known to affect cells and tissues. Greater responsibility for patient safety is now placed on the diagnostician; for the new indexes to be meaningful the diagnostician must be cognizant of the health and safety implications. The purpose of this article is to provide some guidance to the obstetrician in interpreting the indexes and to review the current status of ultrasonography biophysics in relation to the use of diagnostic ultrasound in obstetrics.

An investigation of the relationship between ultrasound echo enhancement and Doppler frequency shift using a pulsatile arterial flow phantom

RATIONALE AND OBJECTIVES

Based on the echo-enhancing effect of microbubbles, various agents have been developed to improve the diagnostic confidence in patients with inadequate Doppler signals. In the clinical trials of the echo enhancer Levovist, there were a few isolated cases in which the maximum flow velocities of the enhanced Doppler spectra appeared to higher than the velocities in the nonenhanced baseline spectra. This raised the concern that echo enhancement could give a false indication of maximum flow velocity. This study investigated whether a systematic association between echo enhancement and velocity shift exists.

METHODS

A pulsatile flow phantom that simulated the elasticity of blood vessels and the acoustic attenuation of extravascular tissue was used to compare enhanced with unenhanced Doppler spectra under accurately reproducible flow conditions. The experiments were carried out with varied sound attenuation and evaluated with dedicated spectral analysis software that included a special averaging tool.

RESULTS

Levovist enhanced the Doppler signal by 16 to 31 dB, and the enhanced and unenhanced power spectra presented identical distribution of spectral power density under all flow conditions.

CONCLUSIONS

The measurements gave no evidence that echo enhancement with Levovist falsifies the Doppler measurement of flow velocity.

Clinical experience with sonographic contrast agents

Early generations of sonographic contrast agents are beginning to reach the attention of the clinician. Research and development of ultrasound contrast agents is progressing at a rapid pace with several new agents approaching US Food and Drug Administration approval. Cardiac imaging has been affected by even the limited availability of contrast agents on the market today both with regard to diagnosis of shunts and chamber opacification, and most recently actual enhancement of the myocardium. Later generations of contrast are capable of providing consistent opacification of both peripheral veins and arteries, and should prove useful in a variety clinical applications. Thus far, it appears that longer vessel segments may be seen with contrast rather than without contrast, and that flow may be demonstrated in vessels which were not seen or thought to be occluded with conventional color imaging. Improved detection of arterial and venous collaterals and enhanced identification of run-off vessels is demonstrated with sonographic contrast agents. An improved ability to evaluate renal artery stenosis and subtotal occlusion of the carotid artery are specific advantages of using contrast as well. Several compounds are currently being tested that may allow routine parenchymal opacification. Ultrasound is the most commonly performed diagnostic imaging procedure; therefore, contrast agents have the potential to dramatically alter the practice of clinical medicine. This article reviews the current status of ultrasound contrast agents and speculates regarding the future applications of these agents.

Ultrasound contrast media and their use in obstetrics and gynecology

Contrast media have gained acceptance to enhance ultrasonography in many fields of medicine; in particular, cardiology. Several agents have been described and many more are being manufactured and tested. By increasing the number of strong sound scatterers, these agents improve images by increasing the amount of echoes. This is true both for grey-scale and color or Doppler imaging. Their use in obstetrics is very limited at the moment because of safety issues. In a laboratory setup, they have been shown to markedly enhance placental imaging. In gynecology, imaging of the uterine cavity and Fallopian tubes is greatly improved. A potential area where ultrasound contrast may find a role is gynecological oncology. Vascularity is increased in many tumors, but usually vessel diameter is small and velocity low. One can therefore expect future use of the ultrasound contrast agents in ovarian or other gynecological neoplasms.

Ultrasound contrast agents: a review

During the past 25 years, many attempts have been made to establish effective ultrasound contrast agents for both cardiac and noncardiac applications. The ideal ultrasound contrast agent would be: (a) nontoxic; (b) injectable intravenously; (c) capable of passing through the pulmonary, cardiac and capillary circulations; and (d) stable for recirculation. A variety of potential ultrasound contrast agents have been or are now under development. Present and future ultrasound contrast agents should provide for increased diagnostic capabilities in a variety of normal and abnormal vessels and organs throughout the body. These agents will enhance tumor vascularity, delineate areas of ischemia, as well as improve visualization of vascular stenosis. Future developments with modification of ultrasound equipment should increase the capabilities of these agents to improve imaging as well as Doppler sensitivity.